Griseofulvin Tablet
NDC Package 0781-5515-01
Package Information
Griseofulvin tablets is uSP are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy, hair and nails, namely:Tinea corporis Tinea pedis Tinea cruris Tinea barbae Tinea capitis Tinea unguium when caused by one or more of the following species of fungi:Epidermophyton floccosum Microsporum audouinii Microsporum canis Microsporum gypseum Trichophyton crateriform Trichophyton gallinae Trichophyton interdigitalis Trichophyton megnini Trichophyton mentagrophytes Trichophyton rubrum Trichophyton schoenleiniTrichophyton sulphureumTrichophyton tonsurans Trichophyton verrucosumNote:Prior to therapy, a dermatophyte should be identified as responsible for the infection.Prior to initiating treatment, appropriate specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis.Griseofulvin tablets, USP are noteffective in the following:Bacterial infectionsCandidiasis (Moniliasis)HistoplasmosisActinomycosisSporotrichosisChromoblastomycosisCoccidioidomycosisNorth American BlastomycosisCryptococcosis (Torulosis)Tinea versicolorNocardiosisThe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone. This formulation utilizes a tablet delivery system. Marketed by Sandoz Inc, this product is identified by NDC 0781-5515 and is authorized under FDA application ANDA091592.
Identification & Billing
- RxCUI: 239239 - griseofulvin 250 MG Oral Tablet
- RxCUI: 310600 - griseofulvin 500 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0781 - Sandoz Inc
- 0781-5515 - Griseofulvin
- 0781-5515-01 - 100 TABLET in 1 BOTTLE
- 0781-5515 - Griseofulvin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0781-5515). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0781-5515-01 identifies a specific commercial package of 100 tablet in 1 bottle of Griseofulvin, a human prescription drug labeled by Sandoz Inc. This tablet is formulated for oral use and contains griseofulvin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sandoz Inc on August 07, 2013. The current certification is valid through December 31, 2027.
How is this Sandoz Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00781551501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.